Guard-Heart Ern on Muck Rack

Guard-Heart Ern

As seen in: The European Heart Journal Podcast
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Guard-Heart

Contact Guard-Heart, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association

|
By Manuel de Falla, CIBER Cardiovascular, Fuencarral-El Pardo, Guard-Heart Ern
| The European Heart Journal Podcast
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and often fatal disease that is increasingly recognized as a frequent cause of progressive heart failure (HF).1 Treatment for ATTR-CM includes both disease specific and non-specific therapies.1–3 Disease specific treatments aim to stop or delay amyloid deposition, improving the disease natural course (i.e. ‘disease-modifying therapies’).3 In contrast, non-specific treatment (supportive) therapies do not target the amyloidogenic...
Open in Who Shared Issue with article?
See all 1 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified